当前位置: X-MOL 学术N. Engl. J. Med. › 论文详情
Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer
The New England Journal of Medicine ( IF 70.670 ) Pub Date : 2020-02-13 , DOI: 10.1056/nejmc1916477


This article has no abstract; the first 100 words appear below. To the Editor: In the trial conducted by Coleman et al. (Nov. 14 issue),1 the addition of secondary surgical cytoreduction to platinum-based chemotherapy in patients with platinum-sensitive, recurrent ovarian cancer did not result in prolonged progression-free survival or overall survival, including among patients who underwent complete cytoreductive surgery (who had no overall survival benefit). A similarly designed trial (DESKTOP III) that used a positive Arbeitsgemeinschaft Gynäkologische Onkologie score (Eastern Cooperative Oncology Group performance-status score of 0 [on a 5-point scale, with higher scores indicating greater disability], complete resection at first surgery, and no ascites; a predictive marker for complete cytoreduction) . . .
更新日期:2020-02-13

 

全部期刊列表>>
Springer Nature 2019高下载量文章和章节
化学/材料学中国作者研究精选
《科学报告》最新环境科学研究
ACS材料视界
自然科研论文编辑服务
中南大学国家杰青杨华明
南开大学陈弓课题组招聘启事
中南大学
材料化学和生物传感方向博士后招聘
课题组网站
X-MOL
北京大学分子工程苏南研究院
华东师范大学分子机器及功能材料
中山大学化学工程与技术学院
试剂库存
天合科研
down
wechat
bug